Treatment Approach for Breast Carcinoma
In Situ Disease Management
- The National Comprehensive Cancer Network recommends observation alone as the preferred treatment for Lobular Carcinoma In Situ (LCIS) because the risk of developing invasive carcinoma is low (~21% over 15 years) 1, 2
- LCIS is considered a risk marker for future breast cancer development in either breast, not a malignant lesion requiring surgical excision 3
- Bilateral mastectomy should only be considered in special circumstances such as BRCA1/2 mutation or strong family history, and is NOT recommended for most women with LCIS 1, 2
- Ductal Carcinoma In Situ (DCIS) requires active treatment with breast-conserving surgery plus adjuvant radiation therapy, which benefits all subgroups 4
- Adjuvant tamoxifen should be considered for ER-positive DCIS 4
- Complete excision with negative margins is essential for DCIS 3
- The goal of treating DCIS is preventing development of invasive disease 5, 6
Invasive Disease Management
- Treatment algorithms do NOT differ based on lobular versus ductal histology - both are treated according to stage, hormone receptor status, HER2 status, and risk stratification 1, 2
- Key treatment decisions are based on endocrine responsiveness (ER/PR status) 4
- Risk of relapse (tumor size, grade, nodal status) is also a key factor in treatment decisions 4
- HER2 status is an important consideration in treatment planning 4
- Stage and operability are also crucial in determining the treatment approach 1, 2
- For locally advanced disease (T4), neoadjuvant chemotherapy is indicated regardless of histology, followed by surgery and radiation 7